The Seer device uses conductive sintered steel as an electrode for radio frequency (RF) for cutting and coagulation. The process involves delivery of RF current and sterile saline for resection and coagulation in surgical procedures.
The company anticipates developing additional products based on the Seer technology for use in orthopedic and blood vessel sealing procedures.
Andrew Makrides, president of Bovie, said: “We are pleased to have received FDA 510(k) clearance to market the Seer device in the US having already CE Marked the product for sale in the EU. Bovie’s ability to market the Seer positions the company closer to its goal of increasing shareholder value through the development of proprietary technologies and products.”